Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to Clinic
Shilpa D Kadam1,2, Brennan J Sullivan3, Archita Goyal4
1The Hugo Moser Research Institute at Kennedy Krieger, Baltimore, MD 21205, USA. kadam@kennedykrieger.org.
Abstract:
Rett syndrome (RTT) and CDKL5 deficiency disorder (CDD) are two rare X-linked developmental brain disorders with overlapping but distinct phenotypic features. This review examines the impact of loss of methyl-CpG-binding protein 2 (MeCP2) and cyclin-dependent kinase-like 5 (CDKL5) on clinical phenotype, deficits in synaptic- and circuit-homeostatic mechanisms, seizures, and sleep. In particular, we compare the overlapping and contrasting features between RTT and CDD in clinic and in preclinical studies. Finally, we discuss lessons learned from recent clinical trials while reviewing the findings from pre-clinical studies.
Insights
Rett syndrome (RTT) and CDKL5 deficiency disorder (CDD) are rare X-linked brain disorders. This review compares their clinical features, underlying molecular mechanisms involving MeCP2 and CDKL5, and discusses clinical trial outcomes.
Area of Science:
- Neuroscience
- Genetics
- Developmental Biology
Background:
- Rett syndrome (RTT) and CDKL5 deficiency disorder (CDD) are rare X-linked neurodevelopmental disorders.
- Both conditions stem from mutations in genes critical for brain development and function.
- They present with overlapping yet distinct clinical manifestations, including neurological and developmental challenges.
Purpose of the Study:
- To compare the clinical phenotypes of RTT and CDD.
- To examine the impact of MeCP2 and CDKL5 loss on synaptic and circuit homeostasis, seizures, and sleep.
- To review findings from preclinical studies and recent clinical trials for both disorders.
Main Methods:
- Literature review of preclinical studies on RTT and CDD.
- Analysis of clinical data and trial outcomes for RTT and CDD.
- Comparative analysis of phenotypic features and molecular mechanisms.
Main Results:
- RTT and CDD share some clinical features but exhibit distinct patterns in neurological deficits.
- Loss of MeCP2 (in RTT) and CDKL5 (in CDD) significantly impacts synaptic plasticity and circuit function.
- Seizures and sleep disturbances are common in both disorders, with variations in severity and presentation.
Conclusions:
- Understanding the distinct and overlapping features of RTT and CDD is crucial for targeted therapeutic development.
- Preclinical findings provide insights into disease mechanisms, informing clinical trial design.
- Further research and clinical trials are needed to address the unmet needs in RTT and CDD management.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...